This database contains 168 studies, archived under the term: "adverse effects"
Click here to filter this large number of results.
Clinical rehabilitative effect of memantine on cognitive and motor disorders in patients with Parkinson’s disease
Li, Wei,
Zhao, Jian-Hua,
Sun, Sheng-Gang,
Zhang, Jie-Wen,
Suo, Ai-Qin,
Ma, Ming-Ming
Objective: To study the effects of memantine on cognitive and motor impairment in patients with Parkinson’s disease (PD).; Methods: A total of 55 PD patients complicated by varying degrees of cognitive impairment were randomly divided into two groups. The patients of experimental group (n = 28) received memantine (20 mg/d) while those in the control […]
Ceraxon (citicoline) in the treatment of the mild cognitive impairment syndrome
The objective was to study efficacy and safety of ceraxon (citicoline) used perorally in dose 1000 mg daily in the treatment of cognitive disturbances in patients with amnesic type of mild cognitive impairment (MCI). Twenty patients, aged from 50 to 90 years, received ceraxon in dose 1000 mg twice a day during 90 days. The […]
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Rinne, Juha O.,
Brooks, David J.,
Rossor, Martin N.,
Fox, Nick C.,
Bullock, Roger,
Klunk, William E.,
Mathis, Chester A.,
Blennow, Kaj,
Barakos, Jerome,
Okello, Aren A.,
Rodriguez Martinez de Liano, Sofia,
Liu, Enchi,
Koller, Martin,
Gregg, Keith M.,
Schenk, Dale,
Black, Ronald,
Grundman, Michael
Background: Carbon-11-labelled Pittsburgh compound B ((11)C-PiB) PET is a marker of cortical fibrillar amyloid-beta load in vivo. We used (11)C-PiB PET to investigate whether bapineuzumab, a humanised anti-amyloid-beta monoclonal antibody, would reduce cortical fibrillar amyloid-beta load in patients with Alzheimer’s disease.; Methods: Patients with mild-to-moderate Alzheimer’s disease were randomly assigned to receive intravenous bapineuzumab or […]
Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease
Siemers, Eric R.,
Friedrich, Stuart,
Dean, Robert A.,
Gonzales, Celedon R.,
Farlow, Martin R.,
Paul, Steven M.,
Demattos, Ronald B.
Objectives: Active and passive immunization strategies have been suggested as possible options for the treatment of Alzheimer disease (AD). LY2062430 (solanezumab) is a humanized monoclonal antibody being studied as a putative disease-modifying treatment of AD.; Methods: Patients with mild to moderate AD were screened and selected for inclusion. Initial screening was performed for 54 subjects, […]
A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease
Objectives: To evaluate the safety of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in nondiabetic patients with Alzheimer disease (AD) and to explore treatment effect sizes on clinical outcomes.; Design: Double-blind, placebo-controlled randomized controlled trial of 18-month duration.; Setting: Two academic medical center outpatient clinics.; Patients: Nondiabetic patients meeting research criteria for probable AD were […]
Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers
Serrano-Pozo, Alberto,
Vega, Gloria L.,
Lütjohann, Dieter,
Locascio, Joseph J.,
Tennis, Marsha K.,
Deng, Amy,
Atri, Alireza,
Hyman, Bradley T.,
Irizarry, Michael C.,
Growdon, John H.
Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M.,
Bell, K. L.,
Galasko, D.,
Galvin, J. E.,
Thomas, R. G.,
van Dyck, C. H.,
Aisen, P. S.
Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]
Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD
Vigen, Cheryl L. P.,
Mack, Wendy J.,
Keefe, Richard S. E.,
Sano, Mary,
Sultzer, David L.,
Stroup, T. Scott,
Dagerman, Karen S.,
Hsiao, John K.,
Lebowitz, Barry D.,
Lyketsos, Constantine G.,
Tariot, Pierre N.,
Zheng, Ling,
Schneider, Lon S.
Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]
Effect of Rikkunshi-to on appetite loss found in elderly dementia patients: a preliminary study
Utumi, Yushi,
Iseki, Eizo,
Murayama, Norio,
Nozawa, Motohiro,
Kumagai, Ryo,
Matsubara, Youichiro,
Ichimiya, Yosuke,
Arai, Heii
Background: Functional gastrointestinal symptoms are frequently found in elderly dementia patients. In such a case, we attempt treatment by the administration of antidepressants or second-generation antipsychotics. However, these medications have a risk of side-effects. In the present study, we carried out oral administration of Rikkunshi-to to elderly dementia patients with appetite loss, and examined its […]